26 June 2014 
EMA/CHMP/500946/2014  
Committee for Medicinal Products for Human Use (CHMP) 
Pixuvri 
Scientific conclusions and grounds recommending the variation to the terms 
of the marketing authorisation 
International non-proprietary name: pixantrone dimaleate 
Procedure No.  EMEA/H/C/002055/PSUV/0015 
Period covered by the PSUR: 11 May 2013 – 10 November 2013 
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom 
Telephone  +44 (0)20 3660 6000  Facsimile +44 (0)20 3660 5555 
Send a question via our website www.ema.europa.eu/contact 
An agency of the European Union   
© European Medicines Agency, 2014. Reproduction is authorised provided the source is acknowledged. 
 
 
  
 
 
 
 
 
Scientific conclusions  
Taking into account the PRAC Assessment Report on the PSUR for Pixuvri, the scientific conclusions of 
PRAC are as follows:  
Based on the PRAC review of data on safety and efficacy, the PRAC considers that the risk-benefit 
balance of medicinal products containing the active substance pixantrone remains favourable but 
recommends that the terms of the marketing authorisation should be varied as based on the data from 
the PSUR, updates to section 4.4 and 4.8 of the SmPC with respect to secondary malignancies 
(specifically AML and MDS) are required. The package leaflet is updated accordingly.The CHMP agrees 
with the scientific conclusions made by the PRAC. 
Grounds recommending the variation to the terms of the Marketing Authorisation  
On the basis of the scientific conclusions for Pixuvri, the CHMP is of the opinion that the benefit-risk 
balance of the medicinal product containing the active substance pixantrone dimaleate is favourable 
subject to the proposed changes to the product information. 
The CHMP recommends that the terms of the Marketing Authorisation(s) should be varied. 
Pixuvri  
EMA/CHMP/500946/2014  
Page 2/2 
 
 
 
 
 
 
 
